 Sridharan Raghavan
Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 32 | 2026 | 2584 | 3.880 |
Why?
| | Cardiovascular Diseases | 11 | 2025 | 2171 | 1.760 |
Why?
| | Diabetes Mellitus | 7 | 2025 | 1098 | 1.540 |
Why?
| | Veterans | 10 | 2025 | 1603 | 1.480 |
Why?
| | Blood Glucose | 16 | 2026 | 2330 | 1.300 |
Why?
| | Hypoglycemic Agents | 6 | 2025 | 1389 | 1.040 |
Why?
| | Life Style | 4 | 2025 | 479 | 1.020 |
Why?
| | Genetic Predisposition to Disease | 11 | 2025 | 2365 | 0.850 |
Why?
| | Hypertension | 3 | 2025 | 1264 | 0.840 |
Why?
| | Genome-Wide Association Study | 14 | 2026 | 1407 | 0.790 |
Why?
| | Myocardial Infarction | 4 | 2025 | 1209 | 0.780 |
Why?
| | Dementia, Vascular | 1 | 2022 | 21 | 0.760 |
Why?
| | Metformin | 2 | 2025 | 319 | 0.730 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2025 | 250 | 0.720 |
Why?
| | Risk Factors | 22 | 2025 | 10792 | 0.680 |
Why?
| | Machine Learning | 4 | 2022 | 587 | 0.680 |
Why?
| | Coronary Artery Disease | 4 | 2022 | 741 | 0.660 |
Why?
| | Hypoglycemia | 1 | 2025 | 477 | 0.650 |
Why?
| | Polymorphism, Single Nucleotide | 13 | 2026 | 2147 | 0.630 |
Why?
| | Antihypertensive Agents | 2 | 2025 | 511 | 0.620 |
Why?
| | Alzheimer Disease | 2 | 2023 | 622 | 0.600 |
Why?
| | Early Medical Intervention | 1 | 2019 | 61 | 0.580 |
Why?
| | Genetic Counseling | 1 | 2019 | 81 | 0.570 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 439 | 0.550 |
Why?
| | Fasting | 4 | 2025 | 277 | 0.540 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 222 | 0.530 |
Why?
| | Models, Statistical | 2 | 2021 | 682 | 0.530 |
Why?
| | Secondary Prevention | 1 | 2019 | 255 | 0.520 |
Why?
| | Weight Loss | 2 | 2021 | 837 | 0.510 |
Why?
| | Behavior Therapy | 1 | 2019 | 299 | 0.470 |
Why?
| | Atrial Fibrillation | 1 | 2022 | 550 | 0.470 |
Why?
| | Research Design | 2 | 2021 | 1137 | 0.460 |
Why?
| | Humans | 55 | 2026 | 144957 | 0.460 |
Why?
| | Population Surveillance | 1 | 2019 | 485 | 0.450 |
Why?
| | Aged | 22 | 2025 | 25947 | 0.440 |
Why?
| | Middle Aged | 27 | 2026 | 35928 | 0.430 |
Why?
| | Risk Assessment | 4 | 2024 | 3676 | 0.400 |
Why?
| | Obesity | 5 | 2025 | 3082 | 0.400 |
Why?
| | Multifactorial Inheritance | 5 | 2025 | 203 | 0.390 |
Why?
| | Incidence | 8 | 2025 | 2883 | 0.380 |
Why?
| | Adult | 21 | 2025 | 40506 | 0.370 |
Why?
| | Mycobacterium tuberculosis | 4 | 2008 | 337 | 0.350 |
Why?
| | Insulin Resistance | 3 | 2021 | 1241 | 0.350 |
Why?
| | Social Support | 1 | 2016 | 652 | 0.350 |
Why?
| | Prediabetic State | 2 | 2025 | 245 | 0.350 |
Why?
| | United States | 13 | 2026 | 15988 | 0.340 |
Why?
| | Metabolic Syndrome | 1 | 2015 | 354 | 0.340 |
Why?
| | Male | 31 | 2026 | 72406 | 0.320 |
Why?
| | Virulence Factors | 2 | 2008 | 174 | 0.310 |
Why?
| | Retrospective Studies | 11 | 2025 | 17101 | 0.310 |
Why?
| | Female | 31 | 2026 | 78376 | 0.310 |
Why?
| | Body Mass Index | 5 | 2025 | 2438 | 0.280 |
Why?
| | Atherosclerosis | 2 | 2024 | 409 | 0.280 |
Why?
| | Follow-Up Studies | 5 | 2025 | 5417 | 0.270 |
Why?
| | Bacterial Proteins | 3 | 2008 | 962 | 0.250 |
Why?
| | Transcription Factor 7-Like 2 Protein | 1 | 2025 | 26 | 0.230 |
Why?
| | Quantitative Trait Loci | 2 | 2026 | 374 | 0.230 |
Why?
| | Genetic Variation | 2 | 2025 | 984 | 0.230 |
Why?
| | Hyperinsulinism | 1 | 2025 | 113 | 0.210 |
Why?
| | Survival Rate | 2 | 2019 | 2092 | 0.200 |
Why?
| | Longevity | 1 | 2025 | 173 | 0.200 |
Why?
| | Precision Medicine | 2 | 2026 | 458 | 0.190 |
Why?
| | Insulin | 4 | 2025 | 2507 | 0.190 |
Why?
| | Biguanides | 1 | 2022 | 10 | 0.190 |
Why?
| | Selection Bias | 1 | 2022 | 38 | 0.180 |
Why?
| | Comorbidity | 2 | 2018 | 1660 | 0.180 |
Why?
| | Calibration | 1 | 2022 | 151 | 0.180 |
Why?
| | Causality | 1 | 2022 | 126 | 0.180 |
Why?
| | Veterans Health | 2 | 2020 | 189 | 0.180 |
Why?
| | Transcription Factors | 2 | 2016 | 1742 | 0.170 |
Why?
| | Chromosome Mapping | 1 | 2022 | 510 | 0.170 |
Why?
| | Body Height | 1 | 2022 | 202 | 0.170 |
Why?
| | Entropy | 1 | 2021 | 45 | 0.170 |
Why?
| | Coronary Disease | 1 | 2023 | 386 | 0.170 |
Why?
| | Case-Control Studies | 2 | 2025 | 3608 | 0.170 |
Why?
| | Insurance Carriers | 1 | 2021 | 13 | 0.170 |
Why?
| | Ambulatory Care | 1 | 2025 | 603 | 0.160 |
Why?
| | Adiposity | 1 | 2025 | 543 | 0.160 |
Why?
| | Cause of Death | 2 | 2022 | 472 | 0.160 |
Why?
| | Probability | 1 | 2021 | 312 | 0.160 |
Why?
| | Colonic Neoplasms | 1 | 2022 | 260 | 0.160 |
Why?
| | Insulin-Secreting Cells | 1 | 2024 | 388 | 0.150 |
Why?
| | Diabetic Retinopathy | 1 | 2022 | 208 | 0.150 |
Why?
| | Nutrition Surveys | 1 | 2021 | 282 | 0.150 |
Why?
| | Macrophages | 5 | 2008 | 1511 | 0.150 |
Why?
| | Longitudinal Studies | 2 | 2018 | 2947 | 0.150 |
Why?
| | Guidelines as Topic | 1 | 2021 | 268 | 0.140 |
Why?
| | Coronary Artery Bypass | 1 | 2021 | 269 | 0.140 |
Why?
| | Cigarette Smoking | 1 | 2020 | 99 | 0.140 |
Why?
| | Mendelian Randomization Analysis | 3 | 2023 | 55 | 0.140 |
Why?
| | Diabetic Nephropathies | 1 | 2022 | 318 | 0.140 |
Why?
| | Insurance, Health | 1 | 2021 | 303 | 0.140 |
Why?
| | Diabetes Complications | 1 | 2019 | 223 | 0.130 |
Why?
| | Patient Readmission | 1 | 2023 | 759 | 0.130 |
Why?
| | Exercise | 2 | 2021 | 2201 | 0.130 |
Why?
| | Virulence | 3 | 2008 | 280 | 0.130 |
Why?
| | Clinical Trials as Topic | 1 | 2022 | 1054 | 0.130 |
Why?
| | Tachycardia, Ventricular | 1 | 2018 | 181 | 0.120 |
Why?
| | Risk | 2 | 2020 | 911 | 0.120 |
Why?
| | Blood Pressure | 2 | 2022 | 1769 | 0.120 |
Why?
| | Bariatric Surgery | 1 | 2020 | 242 | 0.120 |
Why?
| | Obesity, Morbid | 1 | 2020 | 281 | 0.120 |
Why?
| | Refugees | 1 | 2016 | 83 | 0.110 |
Why?
| | Family Health | 1 | 2016 | 191 | 0.110 |
Why?
| | Mortality | 1 | 2018 | 376 | 0.110 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2021 | 543 | 0.110 |
Why?
| | Genotype | 1 | 2020 | 1835 | 0.110 |
Why?
| | Mutation Rate | 1 | 2015 | 30 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2015 | 758 | 0.110 |
Why?
| | Defibrillators, Implantable | 1 | 2018 | 382 | 0.110 |
Why?
| | United States Department of Veterans Affairs | 3 | 2025 | 768 | 0.110 |
Why?
| | Spouses | 1 | 2016 | 108 | 0.110 |
Why?
| | Physicians | 1 | 2023 | 940 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1721 | 0.110 |
Why?
| | Gene Expression Regulation, Bacterial | 2 | 2008 | 328 | 0.110 |
Why?
| | Medication Adherence | 1 | 2019 | 539 | 0.110 |
Why?
| | Cardiac Catheterization | 1 | 2018 | 560 | 0.100 |
Why?
| | Emigrants and Immigrants | 1 | 2016 | 158 | 0.100 |
Why?
| | Exome | 1 | 2015 | 227 | 0.100 |
Why?
| | Prognosis | 2 | 2019 | 4293 | 0.100 |
Why?
| | Tuberculosis | 2 | 2008 | 291 | 0.090 |
Why?
| | Heart Failure | 1 | 2025 | 2323 | 0.090 |
Why?
| | Cohort Studies | 4 | 2025 | 5965 | 0.090 |
Why?
| | Age Factors | 1 | 2019 | 3335 | 0.080 |
Why?
| | Stroke | 1 | 2019 | 1258 | 0.080 |
Why?
| | Telemedicine | 1 | 2020 | 948 | 0.080 |
Why?
| | Young Adult | 4 | 2021 | 14126 | 0.080 |
Why?
| | Sample Size | 2 | 2022 | 123 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2925 | 0.080 |
Why?
| | Treatment Outcome | 2 | 2021 | 11695 | 0.070 |
Why?
| | Mycobacterium marinum | 1 | 2008 | 4 | 0.070 |
Why?
| | Genomics | 2 | 2025 | 836 | 0.070 |
Why?
| | Gene Frequency | 2 | 2022 | 481 | 0.070 |
Why?
| | Operon | 1 | 2008 | 69 | 0.070 |
Why?
| | Lysosomes | 1 | 2008 | 128 | 0.070 |
Why?
| | Time Factors | 1 | 2019 | 7183 | 0.070 |
Why?
| | Nod2 Signaling Adaptor Protein | 1 | 2008 | 34 | 0.070 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 2 | 2020 | 88 | 0.070 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2024 | 3890 | 0.060 |
Why?
| | Logistic Models | 2 | 2025 | 2119 | 0.060 |
Why?
| | Listeria monocytogenes | 1 | 2008 | 116 | 0.060 |
Why?
| | Toll-Like Receptors | 1 | 2008 | 194 | 0.060 |
Why?
| | Phagocytosis | 1 | 2008 | 299 | 0.060 |
Why?
| | Genetic Loci | 2 | 2020 | 261 | 0.060 |
Why?
| | Transcriptional Activation | 1 | 2008 | 383 | 0.060 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2026 | 103 | 0.060 |
Why?
| | Immunity, Cellular | 1 | 2008 | 272 | 0.060 |
Why?
| | Glucose | 2 | 2021 | 1049 | 0.060 |
Why?
| | CpG Islands | 1 | 2025 | 165 | 0.060 |
Why?
| | Whole Genome Sequencing | 1 | 2026 | 183 | 0.060 |
Why?
| | Anthropometry | 1 | 2025 | 200 | 0.050 |
Why?
| | Body Size | 1 | 2025 | 95 | 0.050 |
Why?
| | Transcription, Genetic | 2 | 2008 | 1496 | 0.050 |
Why?
| | Mice, Inbred C57BL | 4 | 2008 | 5997 | 0.050 |
Why?
| | Sensitivity and Specificity | 2 | 2019 | 1990 | 0.050 |
Why?
| | Promoter Regions, Genetic | 1 | 2008 | 1258 | 0.050 |
Why?
| | Phenotype | 2 | 2022 | 3164 | 0.050 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2008 | 366 | 0.050 |
Why?
| | Clonal Evolution | 1 | 2023 | 47 | 0.050 |
Why?
| | Registries | 2 | 2025 | 2385 | 0.050 |
Why?
| | Hematopoiesis | 1 | 2023 | 194 | 0.050 |
Why?
| | Linkage Disequilibrium | 1 | 2022 | 247 | 0.040 |
Why?
| | Skilled Nursing Facilities | 1 | 2023 | 151 | 0.040 |
Why?
| | Prospective Studies | 2 | 2024 | 7997 | 0.040 |
Why?
| | Europe | 1 | 2022 | 412 | 0.040 |
Why?
| | Biological Specimen Banks | 1 | 2022 | 103 | 0.040 |
Why?
| | Albuminuria | 1 | 2022 | 190 | 0.040 |
Why?
| | United Kingdom | 1 | 2022 | 338 | 0.040 |
Why?
| | Haplotypes | 1 | 2022 | 490 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 685 | 0.040 |
Why?
| | American Heart Association | 1 | 2022 | 350 | 0.040 |
Why?
| | DNA Methylation | 1 | 2025 | 683 | 0.040 |
Why?
| | Fee-for-Service Plans | 1 | 2021 | 98 | 0.040 |
Why?
| | Genome, Human | 1 | 2022 | 422 | 0.040 |
Why?
| | Cholesterol, LDL | 1 | 2022 | 358 | 0.040 |
Why?
| | Mice | 5 | 2008 | 18365 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2023 | 732 | 0.040 |
Why?
| | Sodium | 1 | 2020 | 197 | 0.040 |
Why?
| | Decision Trees | 1 | 2018 | 81 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2609 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2022 | 760 | 0.030 |
Why?
| | Exercise Test | 1 | 2021 | 634 | 0.030 |
Why?
| | Medicare | 1 | 2023 | 887 | 0.030 |
Why?
| | ROC Curve | 1 | 2019 | 615 | 0.030 |
Why?
| | Homeostasis | 1 | 2021 | 640 | 0.030 |
Why?
| | Patient Discharge | 1 | 2023 | 983 | 0.030 |
Why?
| | Odds Ratio | 1 | 2019 | 1077 | 0.030 |
Why?
| | Massachusetts | 1 | 2016 | 180 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2016 | 105 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2020 | 1095 | 0.030 |
Why?
| | Introns | 1 | 2016 | 254 | 0.030 |
Why?
| | Glucose-6-Phosphatase | 1 | 2015 | 31 | 0.030 |
Why?
| | Enhancer Elements, Genetic | 1 | 2016 | 192 | 0.030 |
Why?
| | Cells, Cultured | 3 | 2008 | 4155 | 0.030 |
Why?
| | Animals | 5 | 2008 | 38109 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2025 | 5872 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2016 | 1325 | 0.020 |
Why?
| | Hospitalization | 1 | 2023 | 2434 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2015 | 373 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2017 | 2029 | 0.020 |
Why?
| | Pilot Projects | 1 | 2018 | 1890 | 0.020 |
Why?
| | Mutation | 1 | 2023 | 4099 | 0.020 |
Why?
| | Adolescent | 2 | 2021 | 22453 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3415 | 0.020 |
Why?
| | Mass Screening | 1 | 2019 | 1348 | 0.020 |
Why?
| | Islets of Langerhans | 1 | 2016 | 833 | 0.020 |
Why?
| | CARD Signaling Adaptor Proteins | 1 | 2008 | 22 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2016 | 1177 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 8279 | 0.020 |
Why?
| | Pregnancy | 1 | 2021 | 7191 | 0.020 |
Why?
| | Caspase 1 | 1 | 2008 | 148 | 0.020 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2008 | 44 | 0.020 |
Why?
| | Cytoskeletal Proteins | 1 | 2008 | 156 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2008 | 187 | 0.020 |
Why?
| | Macrophage Activation | 1 | 2008 | 193 | 0.020 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2008 | 169 | 0.020 |
Why?
| | Interleukin-18 | 1 | 2008 | 235 | 0.020 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2008 | 116 | 0.020 |
Why?
| | Gene Silencing | 1 | 2008 | 205 | 0.020 |
Why?
| | Hemolysis | 1 | 2008 | 243 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 4275 | 0.010 |
Why?
| | Interleukin-1beta | 1 | 2008 | 395 | 0.010 |
Why?
| | Genetic Complementation Test | 1 | 2005 | 66 | 0.010 |
Why?
| | Two-Hybrid System Techniques | 1 | 2005 | 59 | 0.010 |
Why?
| | Culture Media, Conditioned | 1 | 2005 | 111 | 0.010 |
Why?
| | Genes, Bacterial | 1 | 2005 | 166 | 0.010 |
Why?
| | Multigene Family | 1 | 2005 | 204 | 0.010 |
Why?
| | Antigens, Bacterial | 1 | 2005 | 127 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2008 | 737 | 0.010 |
Why?
| | Conserved Sequence | 1 | 2003 | 245 | 0.010 |
Why?
| | Plasmids | 1 | 2003 | 379 | 0.010 |
Why?
| | Calcium | 1 | 2008 | 1184 | 0.010 |
Why?
| | Protein Transport | 1 | 2003 | 441 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2005 | 2157 | 0.010 |
Why?
| | Child | 1 | 2021 | 22657 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2931 | 0.010 |
Why?
| | Viral Proteins | 1 | 2003 | 355 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2008 | 1786 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2008 | 3125 | 0.010 |
Why?
| | Inflammation | 1 | 2008 | 2880 | 0.010 |
Why?
| | Models, Biological | 1 | 2003 | 1822 | 0.010 |
Why?
| | Signal Transduction | 1 | 2008 | 5233 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2003 | 4569 | 0.010 |
Why?
|
|
Raghavan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|